Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, September 2009, p. 4015-4018, Vol. 53, No. 9
0066-4804/09/$08.00+0 doi:10.1128/AAC.00590-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

kovierová,1
Michael Niederweis,3
Jean-Louis Gaillard,4,5
Gerald McDonnell,6 and
Mary Jackson1*
Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523-1682,1 Department of Biochemistry, Faculty of Natural Sciences, Comenius University, Mlynska dolina CH-1, 84215 Bratislava, Slovak Republic,2 Department of Microbiology, University of Alabama at Birmingham, 609 Bevill Biomedical Research Building, 845 19th Street South, Birmingham, Alabama 35294,3 Laboratoire de Microbiologie, Hôpital Ambroise Paré (Assistance Publique—Hôpitaux de Paris), F-92104 Boulogne Cedex, France,4 EA 3647, Faculté de Médecine de Paris-Ile de France-Ouest, Université de Versailles Saint-Quentin-en-Yvelines, F-92380 Garches, France,5 STERIS Limited, Jays Close, Basingstoke, England RG21 3DP6
Received 1 May 2009/ Returned for modification 28 May 2009/ Accepted 25 June 2009
Nosocomial outbreaks attributable to glutaraldehyde-resistant, rapidly growing mycobacteria are increasing. Here, evidence is provided that defects in porin expression dramatically increase the resistance of Mycobacterium smegmatis and Mycobacterium chelonae to glutaraldehyde and another aldehyde disinfectant, ortho-phthalaldehyde. Since defects in porin activity also dramatically increased the resistance of M. chelonae to drugs, there is thus some concern that the widespread use of glutaraldehyde and ortho-phthalaldehyde in clinical settings may select for drug-resistant bacteria.
Published ahead of print on 6 July 2009.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»